If you are looking at cell therapy for diabetes, the useful question is whether your diabetes type and risk profile match a pathway supported by real human data.
For diabetes, donor islets, stem-cell-derived islets and generic commercial cell infusions have different evidence and regulatory status.
Lantidra is FDA-approved for adults with Type 1 diabetes who cannot approach target HbA1c because of repeated severe hypoglycemia despite intensive diabetes management and education. It is made from deceased-donor pancreatic islets, not stem cells.[1]
Approved, narrow indicationZimislecel is a stem-cell-derived islet-cell therapy infused into the portal vein with immunosuppression. Early results are encouraging, but it remains investigational. On 3 August 2026, Vertex reported that its Phase 1/2/3 study continued to enroll and dose patients.[2][3]
InvestigationalThe FDA’s current approved cellular and gene therapy list does not include a stem-cell therapy for Type 2 diabetes. FDA also continues to warn patients about unapproved human cell and tissue products promoted online for disease treatment.[4][5]
Verify before paying
The strongest current numbers come from small, selected Type 1 diabetes groups. Read the percentage together with the sample size, study design and follow-up.
Two prospective, open-label, single-arm studies included 30 people. Median age was 46.5 years, 80% were women and all participants were White. This is a small, non-diverse dataset, so the observed rates should not be treated as an individual prediction.[8]
Participants could receive up to three infusions. Eleven received one infusion, 12 received two and 7 received three. FDA labeling also states that insulin independence may take weeks and can later be lost.[8]
All 12 full-dose participants spent more than 70% of time in the 70–180 mg/dL CGM range. All participants received immunosuppression. The analyses were interim and not prespecified, and the authors described the study as small and short-term.[2]
It is not the same product as a stem-cell-derived islet therapy, but it shows what beta-cell replacement can achieve and what long-term immunosuppression can cost.
The study was single-arm and enrolled people with Type 1 diabetes, impaired awareness of hypoglycemia and severe hypoglycemic events despite expert care. These results support a narrow high-risk population, not routine diabetes treatment.[12]
The sponsor’s study page lists ages 18–65, Type 1 diabetes with more than 5 years of insulin dependence, at least two documented severe hypoglycemia episodes in the prior 12 months, stable diabetes treatment and consistent CGM use for at least 3 months before screening. These are trial-specific criteria, not universal rules.[10]
These FDA-label rates come from only 30 Lantidra participants with variable follow-up from 0.3 to 14.5 years. They describe the trial experience and may not match rates in routine practice.[8]
Liver laceration, hematoma, hemorrhage or intra-abdominal bleeding was reported in 13% of the Lantidra dataset; portal-pressure elevation was reported in 7%.
Eight of 30 participants lost islet-cell function after immunosuppression was discontinued. A working graft depends on continued immune suppression.
FDA labeling notes that donor-reactive antibodies can increase after infusion and may affect matching for a future kidney or other organ transplant.
Lantidra labeling advises against treatment during pregnancy because the required immunosuppressive medicines can cause serious harm.
NIDDK states that islet-transplant recipients take immunosuppressants for as long as the transplanted islets are working. Stopping them leads to graft rejection.[9]
Use these endpoints to judge whether a result is clinically meaningful:
No authoritative source provides one universal patient price. Cost depends first on whether you are looking at an approved donor-islet product, a registered research study or an unapproved commercial package.
Cost can include the cell product, portal-vein procedure, monitored stay, immunosuppression, laboratory testing and long-term follow-up. Coverage and patient responsibility vary.
Research-related costs may be paid by the study, while routine care and travel can still create patient expenses. ClinicalTrials.gov advises asking the study contact exactly what is covered.[11]
A high or low package price, IV infusion fee or advertised “cell count” is not evidence of regulatory approval, clinical effectiveness or long-term follow-up quality.
A useful quote should separate the product from everything required around it.
Our service helps you understand what you are being offered, prepare the right records and questions, and communicate clearly before you commit time or money.
We turn scattered reports, glucose records and medication information into a clear case summary for discussion.
We separate approved therapy, registered trials and unapproved commercial claims using published sources.
You receive focused questions about eligibility, immune suppression, expected outcomes, follow-up and total cost.
We can help coordinate communication and support medical-document translation so key details are not lost.
You do not need a perfect medical file. These items are enough to make the first discussion more useful.
If the answers stay vague, slow the process down. FDA continues to warn about unapproved cell and tissue products marketed online for broad disease claims.[5]
Stem-cell-derived islet therapy has produced insulin independence in some early trial participants, but it remains investigational. Current results do not justify calling it an approved cure or guaranteeing insulin independence.
Yes. Lantidra is FDA-approved for a narrow group of adults with repeated severe hypoglycemia despite intensive diabetes management. It uses deceased-donor pancreatic islet cells, not stem-cell-derived cells.[1]
No FDA-approved stem-cell therapy for Type 2 diabetes is currently listed. Research into beta-cell biology continues, but commercial experimental offers should not replace established diabetes management.[4]
No. Some people never become insulin-independent, and some who do later restart insulin. The FDA label also states that insulin independence is not immediate and may take several weeks.[8]
Current Lantidra and published zimislecel approaches use immunosuppression. For donor-islet transplantation, NIDDK states that recipients take these medicines for as long as the graft is working. This is one of the main reasons the risk-benefit decision is limited to selected patients.[9]
Current published studies do not provide a reliable treatment-specific survival percentage and do not establish reversal of existing kidney, eye, nerve, heart or vascular damage. Their main endpoints are glucose control, severe hypoglycemia, insulin use, C-peptide and safety.
There is no single reliable price. First confirm the exact product and pathway. Then ask for an itemized scope covering the cell product, procedure, monitored stay, medicines, tests, follow-up and travel. Research-study costs vary by protocol.[11]
Evidence status can change. Regulatory status, trial recruitment and product information should be rechecked before making a decision.
Share the information you’ve got. We’ll organize it, compare it with published criteria, prepare focused questions, coordinate communication and support medical translation.
